Investing.com - Travere Therapeutics (NASDAQ: TVTX) reported first quarter EPS of $1.51, $2.43 better than the analyst estimate of $-0.92. Revenue for the quarter came in at $41.37M versus the consensus estimate of $44.89M.
Travere Therapeutics's stock price closed at $6.55. It is down -21.08% in the last 3 months and down -61.01% in the last 12 months.
Travere Therapeutics saw 3 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Travere Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Travere Therapeutics's Financial Health score is "fair performance".
Check out Travere Therapeutics's recent earnings performance, and Travere Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar